Timothy Beasley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy Beasley has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Dalton Argean Norwood
Division of General Internal Medicine, University of Alabama at Birmingham , Birmingham, AL
31 shared publications - Douglas R. Morgan
Division of Gastroenterology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
31 shared publications - Eleazar Enrique Montalvan-Sanchez
Section of Digestive Diseases, Department of Medicine, Yale School of Medicine , New Haven, CT
31 shared publications - Ricardo L. Dominguez
Western Honduras Gastric Cancer Program, Ministry of Health, Santa Rosa de Copan, Honduras
25 shared publications - Aida Rodriguez-Murillo
Department of Medicine, University of Nevada Reno , Reno, NV
20 shared publications - Luis Eduardo Bravo
Facultad de Salud, Universidad del Valle. Cali, Colombia
17 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S9 presents laboratory test abnormalities reported as adverse events, including specific analytes and event resolution by treatment arm.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S9 presents laboratory test abnormalities reported as adverse events, including specific analytes and event resolution by treatment arm.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Gastric adenocarcinoma is the fifth leading cause of global cancer mortality and a major health disparity in the United States. Effective chemoprevention strategies are limited for high-risk individuals with gastric premalignant conditions (GPMC). We conducted an NCI Division of Cancer Prevention–funded, double-blinded, phase IIa randomized, placebo-controlled trial evaluating eflornithine for chemoprevention in GPMC (NCT02794428). The study was executed in rural Honduras and Puerto Rico, regions with a high prevalence of Helicobacter pylori and gastric intestinal metaplasia (GIM), from September 2016 to December 2022. Eligible subjects (ages 30–69; H. pylori–positive or H. pylori–negative) were randomized 1:1 to receive 500 mg/day eflornithine or placebo for 18 months. Upper endoscopy was performed at baseline, 6, 18, and 24 months. H. pylori–positive patients were offered antibiotic treatment at 6 months. A total of 211 patients were screened, and 91 were randomized (45 to eflornithine and 46 to placebo). The mean age was 45.2 years (SD 8.8), and 74% were female. At baseline, 46% and 54% had gastric atrophy and GIM, respectively. Eighty percent were H. pylori–positive. Follow-up completion rates were 78 patients (6 months), 69 patients (18 months), and 55 patients (24 months). Eflornithine was well tolerated, with fewer grade 1 to 2 adverse events in the eflornithine group (81 vs. 108, placebo). No significant histology score differences were observed. A significant reduction in DNA damage (pH2AX-positive cells) was observed in the 24-month versus 18-month assessments (P = 0.012). Eflornithine was safe and well tolerated in patients with GPMC. The findings suggest that eflornithine reduces long-term DNA damage, supporting further trials to refine treatment duration and patient selection.Prevention Relevance:Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation—alone or combined with H. pylori eradication—as a strategy to interrupt gastric carcinogenesis in high-risk populations.See related Spotlight, p. 387See related article by Gonzalez-Pons et al., p. 403
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Gastric adenocarcinoma is the fifth leading cause of global cancer mortality and a major health disparity in the United States. Effective chemoprevention strategies are limited for high-risk individuals with gastric premalignant conditions (GPMC). We conducted an NCI Division of Cancer Prevention–funded, double-blinded, phase IIa randomized, placebo-controlled trial evaluating eflornithine for chemoprevention in GPMC (NCT02794428). The study was executed in rural Honduras and Puerto Rico, regions with a high prevalence of Helicobacter pylori and gastric intestinal metaplasia (GIM), from September 2016 to December 2022. Eligible subjects (ages 30–69; H. pylori–positive or H. pylori–negative) were randomized 1:1 to receive 500 mg/day eflornithine or placebo for 18 months. Upper endoscopy was performed at baseline, 6, 18, and 24 months. H. pylori–positive patients were offered antibiotic treatment at 6 months. A total of 211 patients were screened, and 91 were randomized (45 to eflornithine and 46 to placebo). The mean age was 45.2 years (SD 8.8), and 74% were female. At baseline, 46% and 54% had gastric atrophy and GIM, respectively. Eighty percent were H. pylori–positive. Follow-up completion rates were 78 patients (6 months), 69 patients (18 months), and 55 patients (24 months). Eflornithine was well tolerated, with fewer grade 1 to 2 adverse events in the eflornithine group (81 vs. 108, placebo). No significant histology score differences were observed. A significant reduction in DNA damage (pH2AX-positive cells) was observed in the 24-month versus 18-month assessments (P = 0.012). Eflornithine was safe and well tolerated in patients with GPMC. The findings suggest that eflornithine reduces long-term DNA damage, supporting further trials to refine treatment duration and patient selection.Prevention Relevance:Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation—alone or combined with H. pylori eradication—as a strategy to interrupt gastric carcinogenesis in high-risk populations.See related Spotlight, p. 387See related article by Gonzalez-Pons et al., p. 403
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Figure S1 shows the absolute mean pH2AX immunohistochemistry scores (± standard error) at baseline, 6, 18, and 24 months for participants randomized to eflornithine or placebo. No statistically significant differences between groups were observed at any individual time point.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Figure S1 shows the absolute mean pH2AX immunohistochemistry scores (± standard error) at baseline, 6, 18, and 24 months for participants randomized to eflornithine or placebo. No statistically significant differences between groups were observed at any individual time point.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S11 outlines the epidemiologic and demographic representativeness of the study population relative to global gastric cancer and gastric premalignant condition burden, including considerations of sex, age, ethnicity, geography, and H. pylori prevalence.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S11 outlines the epidemiologic and demographic representativeness of the study population relative to global gastric cancer and gastric premalignant condition burden, including considerations of sex, age, ethnicity, geography, and H. pylori prevalence.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S4 displays unadjusted mean ± SD pH2AX scores at each study time point for both treatment groups, along with between-group differences (95% confidence intervals) and p-values.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S4 displays unadjusted mean ± SD pH2AX scores at each study time point for both treatment groups, along with between-group differences (95% confidence intervals) and p-values.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S8 summarizes gastrointestinal adverse events by treatment group, including symptom type, associated conditions, and resolution status.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S8 summarizes gastrointestinal adverse events by treatment group, including symptom type, associated conditions, and resolution status.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S2 summarizes Helicobacter pylori infection status by treatment group at each study time point (baseline, 6, 18, and 24 months), including eradication outcomes, treatment uptake, and compliance rates.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S2 summarizes Helicobacter pylori infection status by treatment group at each study time point (baseline, 6, 18, and 24 months), including eradication outcomes, treatment uptake, and compliance rates.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S10 provides longitudinal laboratory values (median and IQR) for hematologic, renal, and hepatic parameters at baseline, 6, 18, and 24 months by treatment group.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S10 provides longitudinal laboratory values (median and IQR) for hematologic, renal, and hepatic parameters at baseline, 6, 18, and 24 months by treatment group.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S7 reports hearing-related adverse events, including event type, attribution, and resolution status, in participants receiving eflornithine or placebo.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S7 reports hearing-related adverse events, including event type, attribution, and resolution status, in participants receiving eflornithine or placebo.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S6 summarizes serious adverse events (SAEs), including hospitalization status, diagnoses, and mortality outcomes by treatment group.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S6 summarizes serious adverse events (SAEs), including hospitalization status, diagnoses, and mortality outcomes by treatment group.